Citations (19)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Thevaki Wain, Alexandra Pavli, Jillian Wells & Pablo Fernandez-Peñas. (2018) The efficacy and safety of methotrexate versus interferon in cutaneous T-cell lymphomas. Journal of Dermatological Treatment 29:7, pages 715-719.
Read now
Read now
Pooja Virmani, Susan H. Hwang, Justin G. Hastings, Bradley M. Haverkos, Becca Kohnken, Alejandro A Gru, Anjali Mishra, Stephanie K. Fabbro, Steve M. Horwitz & Pierluigi Porcu. (2017) Systemic therapy for cutaneous T-cell lymphoma: who, when, what, and why?. Expert Review of Hematology 10:2, pages 111-121.
Read now
Read now
Manisha R Panchal & Julia J Scarisbrick. (2015) The utility of bexarotene in mycosis fungoides and Sézary syndrome. OncoTargets and Therapy 8, pages 367-373.
Read now
Read now
Articles from other publishers (16)
S. Ingen-Housz-Oro, M. d’Incan & M. Beylot-Barry. (2023) Traitements immunomodulateurs du mycosis fongoïde aux stades précoces. Annales de Dermatologie et de Vénéréologie - FMC 3:3, pages 202-207.
Crossref
Crossref
Brandon Ramchatesingh, Amelia Martínez Villarreal, Domenico Arcuri, François Lagacé, Samy Abu Setah, Fadi Touma, Faris Al-Badarin & Ivan V. Litvinov. (2022) The Use of Retinoids for the Prevention and Treatment of Skin Cancers: An Updated Review. International Journal of Molecular Sciences 23:20, pages 12622.
Crossref
Crossref
Louise Photiou, Carrie van der Weyden, Christopher McCormack & H. Miles Prince. (2018) Systemic Treatment Options for Advanced-Stage Mycosis Fungoides and Sézary Syndrome. Current Oncology Reports 20:4.
Crossref
Crossref
Franz Trautinger, Johanna Eder, Chalid Assaf, Martine Bagot, Antonio Cozzio, Reinhard Dummer, Robert Gniadecki, Claus-Detlev Klemke, Pablo L. Ortiz-Romero, Evangelia Papadavid, Nicola Pimpinelli, Pietro Quaglino, Annamari Ranki, Julia Scarisbrick, Rudolf Stadler, Liisa Väkevä, Maarten H. Vermeer, Sean Whittaker, Rein Willemze & Robert Knobler. (2017) European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome – Update 2017. European Journal of Cancer 77, pages 57-74.
Crossref
Crossref
Vassiliki Mpakou, Evangelia Papadavid, Frieda Kontsioti, Eugene Konsta, Miriam Vikentiou, Aris Spathis, Sotiris Papageorgiou, Diamantina Vasilatou, Konstantinos Gkontopoulos, Efthimia Mpazani, Petros Karakitsos, Dimitrios Rigopoulos, George Dimitriadis & Vasiliki Pappa. (2017) Apoptosis Induction and Gene Expression Profile Alterations of Cutaneous T-Cell Lymphoma Cells following Their Exposure to Bortezomib and Methotrexate. PLOS ONE 12:1, pages e0170186.
Crossref
Crossref
Toshihisa HAMADA. (2017) New Therapeutic Approaches for the Treatment of Cutaneous Lymphoma. Nishi Nihon Hifuka 79:2, pages 123-127.
Crossref
Crossref
R.B. WarrenS.C. WeatherheadC.H. SmithL.S. ExtonM.F. Mohd MustapaB. Kirby, P.D. YesudianP.M. McHenry, K. Gibbon, D.A. Buckley, I. Nasr, V.J. Swale, C.E. Duarte Williamson, T. Leslie, E. Mallon, S. Wakelin, S. Ungureanu, P. Hunasehally, M. Cork, J. Donnelly, C. Saunders & A.G. Brain. (2016) British Association of Dermatologists’ guidelines for the safe and effective prescribing of methotrexate for skin disease 2016. British Journal of Dermatology 175:1, pages 23-44.
Crossref
Crossref
Auris O. Huen & Ellen J. Kim. (2015) The Role of Systemic Retinoids in the Treatment of Cutaneous T-Cell Lymphoma. Dermatologic Clinics 33:4, pages 715-729.
Crossref
Crossref
Alessandra di Masi, Loris Leboffe, Elisabetta De Marinis, Francesca Pagano, Laura Cicconi, Cécile Rochette-Egly, Francesco Lo-Coco, Paolo Ascenzi & Clara Nervi. (2015) Retinoic acid receptors: From molecular mechanisms to cancer therapy. Molecular Aspects of Medicine 41, pages 1-115.
Crossref
Crossref
Daniel Humme, Alexander Nast, Ricardo Erdmann, Staffan Vandersee & Marc Beyer. (2014) Systematic review of combination therapies for mycosis fungoides. Cancer Treatment Reviews 40:8, pages 927-933.
Crossref
Crossref
Rakhshandra Talpur, Andrew Thompson, Pamela Gangar & Madeleine Duvic. (2014) Pralatrexate Alone or in Combination With Bexarotene: Long-Term Tolerability in Relapsed/Refractory Mycosis Fungoides. Clinical Lymphoma Myeloma and Leukemia 14:4, pages 297-304.
Crossref
Crossref
Ilkin Zindanci, Mukaddes Kavala, Zafer Turko?lu, Burce Can, Erman Ozturk, Ebru Zemheri, Ozge Akbulak, Cem Mansuroglu & Filiz Topalo?lu Demir. (2014) A CD30(?) Transformed Mycosis Fungoides Case Responding Very Well to Systemic Bexarotene and Methotrexate. The International Journal of Lower Extremity Wounds 13:2, pages 127-129.
Crossref
Crossref
Courtney R. Schadt. (2013) Topical and oral bexarotene. Dermatologic Therapy 26:5, pages 400-403.
Crossref
Crossref
J.J. Scarisbrick, S. Morris, R. Azurdia, T. Illidge, E. Parry, R. Graham-Brown, R. Cowan, E. Gallop-Evans, R. Wachsmuth, M. Eagle, A.S. Wierzbicki, H. Soran, S. Whittaker & E.M. Wain. (2013) U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma. British Journal of Dermatology 168:1, pages 192-200.
Crossref
Crossref
Donald J. AbrahamMarcia I. Dawson. 2003. Burger's Medicinal Chemistry and Drug Discovery. Burger's Medicinal Chemistry and Drug Discovery
369
546
.
Liyan Qu & Xiuwen Tang. (2009) Bexarotene: a promising anticancer agent. Cancer Chemotherapy and Pharmacology 65:2, pages 201-205.
Crossref
Crossref